Virginia Kaklamani, MD, DSc

Kalinsky K et al. Randomized phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4/6 inhibition in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: MAINTAIN trial. J Clin Oncol 2023;41(24):4004-13. Abstract

Llombart-Cussac A et al. Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial. ASCO 2023;Abstract 1001.

Lu YS et al. Primary results from the randomized Phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2− advanced breast cancer treated with ribociclib + endocrine therapy vs physician’s choice combination chemotherapy. SABCS 2022;Abstract GS1-10.

Mayer EL et al. Palbociclib after CDK4/6i and endocrine therapy (PACE): A randomized phase ii study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+/HER2- metastatic breast cancer. SABCS 2022;Abstract GS3-06.

Sonke GS et al. Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC). ASCO 2023;Abstract LBA1000.

Komal Jhaveri, MD, FACP

Howell SJ et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): Overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. Lancet Oncol 2022;23(7):851-64. Abstract

Turner NC et al. Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Results from the Phase III CAPItello-291 trial. SABCS 2023;Abstract GS3-04.

Turner NC et al. Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med 2023;388(22):2058-70. Abstract

Varkaris A et al. Pan-mutant and isoform selective PI3Kα inhibitor, RLY-2608, demonstrates selective targeting in a first-in-human study of PIK3CA-mutant solid tumor patients, ReDiscover trial. AACR 2023;Abstract CT017.

Hope S Rugo, MD

Abelman RO et al. Sequential use of antibody-drug conjugate after antibody-drug conjugate for patients with metastatic breast cancer: ADC after ADC (A3) study. ASCO 2023;Abstract 1022.

Marmé F et al. Real-world data of olaparib maintenance therapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer: Final results of the C-PATROL study. Ann Oncol 2023;34(S2):S535-6. Abstract

Modi S et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 2022;387:9-20. Abstract

Mosele F et al. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: The phase 2 DAISY trial. Nature Med 2023;29(8):2110-20. Abstract

Nelson RS, et al. UGT1A1 guided cancer therapy: Review of the evidence and considerations for clinical implementation. Cancers 2021;13(7):1566. Abstract

Powell CA et al. Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies. ESMO Open 2022;7(4). Abstract

Rugo HS et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): A randomised, open-label, multicentre, phase 3 trial. Lancet 2023;402(10411):1423-33. Abstract

Rugo HS et al. Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ Breast Cancer 2022;8:98. Abstract

Schmid P et al. Trastuzumab deruxtecan (T-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic hormone receptor-negative (HR-), HER2-low breast cancer: Updated results from BEGONIA, a phase 1b/2 study. SABCS 2022;Abstract PD11-08.

Tolaney SM et al. Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC). ASCO 2023;Abstract 1003.

Francois-Clement Bidard, MD, PhD

Bardia A et al. EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting. SABCS 2022;Abstract GS3-01.

Bidard F-C et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Results from the randomized phase III EMERALD trial. J Clin Oncol 2022;40(28):3246-56. Abstract

Jhaveri K et al. Imlunestrant with or without everolimus or alpelisib, in ER+, HER2- advanced breast cancer (aBC): Results from the phase Ia/b EMBER study. ESMO 2023;Abstract 383MO.

Martin Jimenez M et al. Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study. ESMO 2022;Abstract 211MO.

Oliveira M et al. Camizestrant, a next-generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial. SABCS 2022;Abstract GS3-02.

Xu B et al. Updated overall survival (OS) results from the phase 3 PHOEBE trial of pyrotinib versus lapatinib in combination with capecitabine in patients with HER2-positive metastatic breast cancer. SABCS 2022;Abstract GS3-01.

Erika Hamilton, MD

Bardia A et al. Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial. ESMO 2023;Abstract LBA11.

Hamilton EP et al. A phase 2 study of HER3-DXd in patients (pts) with metastatic breast cancer (MBC). ASCO 2023;Abstract 1004.

Krop IE et al. Patritumab deruxtecan (HER3-DXd), a human epidermal growth factor receptor 3-directed antibody-drug conjugate, in patients with previously treated human epidermal growth factor receptor 3-expressing metastatic breast cancer: A multicenter, phase I/II trial. J Clin Oncol 2023;[Online ahead of print]. Abstract

Krop IE et al. Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC). ASCO 2022;Abstract 1002.

Pistilli B et al. A phase 2 study of patritumab deruxtecan (HER3-DXd), in patients (pts) with advanced breast cancer (ABC), with biomarker analysis to characterize response to therapy (ICARUS-BREAST01). ESMO Breast 2023;Abstract 1890.

Uliano J et al. Targeting HER3 for cancer treatment: A new horizon for an old target. ESMO Open 2023;8(1):100790. Abstract

Weng W et al. Antibody-exatecan conjugates with a novel self-immolative moiety overcome resistance in colon and lung cancer. Cancer Discov 2023;13(4):950-73. Abstract

Wu L et al. IN10018 in combination with pegylated liposomal doxorubicin (PLD) in platinum-resistant ovarian cancer (PROC): A single-arm, phase Ib clinical trial. ESMO 2023;Abstract 753P.

Yin Y et al. Epigenetic reprogramming induced prostaglandin E2 accumulation via overactivated arachidonic acid metabolism during trastuzumab resistance formation of HER2-positive breast cancer. ESMO 2023;Abstract 32P.